Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 11

Trial readouts

Semaglutide-Tirzepatide Switching Evidence

A 2026 consensus paper proposes approximate semaglutide-tirzepatide switching bands, but no prospective trial has validated exact conversions.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide at 12 Months: Real-World Data

A US records study reports 12-month weight changes in persistent tirzepatide users without diabetes, with important selection limits.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

How Tirzepatide Works, Without the Jargon

Tirzepatide activates GIP and GLP-1 receptors. Here is what that changes, what dual agonist means, and what mechanism alone cannot prove.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide and Severe Hyponatremia

A 2026 case report links tirzepatide temporally with severe SIADH-compatible hyponatremia, but one case cannot establish causality or frequency.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tirzepatide Side Effects: Trial Findings

Trial rates show gastrointestinal effects are most common. Here is how the FDA labels separate common reactions, serious risks, and the boxed warning.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tirzepatide and WADA: Current Sport Status

Tirzepatide is not named on the 2026 WADA Prohibited List. Here is how named listing, catch-all scope, monitoring, and product risk differ.

3 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

What Is Tirzepatide? Plain-English Guide

Tirzepatide activates GIP and GLP-1 receptors. Learn what it is, how it works, its approved uses, evidence, risks, and open questions.

3 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

ATTAIN-J Orforglipron Trial Results

ATTAIN-J found greater weight loss with oral orforglipron than placebo in Japanese adults, with gastrointestinal tolerability limits.

2 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Dual and Triple Agonists for MASLD

A 2026 review maps dual and triple agonists for MASLD, but the underlying trials use different liver-fat, MASH and fibrosis endpoints.

2 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 Drugs and Neurodegeneration Trials

A 2026 review finds strong biological ideas for GLP-1 drugs in brain disease, but the largest Alzheimer's and Parkinson's trials were negative.

2 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Therapy in Type 1 Diabetes: Evidence

A 2026 review weighs GLP-1-based therapy in type 1 diabetes against small tirzepatide and semaglutide trial safety signals.

2 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

How TB-500 Is Thought to Work

TB-500 mechanism claims often borrow from full-length thymosin beta-4, although the fragment lacks validated biological or clinical equivalence.

2 Nov 2026 · PeptideMethods Editorial Team · 4 min read